Overview

A Phase 3 Study to Evaluate Petosemtamab Compared With Investigator's Choice Monotherapy in Previously Treated Head and Neck Squamous Cell Carcinoma Patients

Status:
RECRUITING
Trial end date:
2029-03-01
Target enrollment:
Participant gender:
Summary
This is a phase 3 open-label, randomized, controlled, multicenter study to compare petosemtamab vs investigator's choice monotherapy in HNSCC patients for the second- and third-line treatment of incurable metastatic/recurrent disease.
Phase:
PHASE3
Details
Lead Sponsor:
Merus N.V.